weight-loss

News

Novo Nordisk's triple-action obesity therapy UBT251, licensed in a $2bn deal last year, achieved almost 20% weight loss in a mid-stage trial.

R&D

Using IP intelligence to guide R&D activity can also help companies to develop treatments that are more effective, with fewer side effects.

Patients

A critical issue within the pharmaceutical sector has been highlighted by the MHRA’s investigation into the improper prescription of Wegovy.

Market Access

Obesity rates in the United States have tripled since the 1980s. According to the CDC, a mind-boggling 41.9% of adults were obese as of 2020.

Market Access

Has the industry found a new revenue driver in weight-loss treatments?